Total Payments
$5.0M
2024 Payments
$1.0M
Companies
57
Transactions
4,245
Medicare Patients
11,237
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$3.6M (71.1%)
Research$564,262 (11.2%)
Consulting$469,799 (9.4%)
Travel$331,292 (6.6%)
Food & Beverage$82,907 (1.7%)
Education$2,746 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.5M | 1,301 | 70.3% |
| Unspecified | $564,262 | 24 | 11.2% |
| Consulting Fee | $469,799 | 152 | 9.4% |
| Travel and Lodging | $331,292 | 1,407 | 6.6% |
| Food and Beverage | $82,907 | 1,338 | 1.7% |
| Honoraria | $32,040 | 12 | 0.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $5,000 | 2 | 0.1% |
| Education | $2,746 | 8 | 0.1% |
| Grant | $1,000 | 1 | 0.0% |
Payments by Type
General
$4.5M
4,221 transactions
Research
$564,262
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $551,035 | 15 | $0 (2024) |
| Amarin Pharma Inc. | $471,566 | 546 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $433,973 | 432 | $0 (2024) |
| Novo Nordisk Inc | $431,152 | 206 | $0 (2024) |
| Lilly USA, LLC | $400,895 | 314 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $378,855 | 372 | $0 (2024) |
| Amgen Inc. | $358,875 | 485 | $0 (2024) |
| Esperion Therapeutics, Inc. | $302,517 | 230 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $283,555 | 256 | $0 (2024) |
| Merck Sharp & Dohme LLC | $279,798 | 253 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1.0M | 408 | Eli Lilly and Company ($475,669) |
| 2023 | $472,662 | 386 | Merck Sharp & Dohme LLC ($92,396) |
| 2022 | $489,270 | 443 | Merck Sharp & Dohme LLC ($105,849) |
| 2021 | $559,167 | 433 | Esperion Therapeutics, Inc. ($147,953) |
| 2020 | $429,709 | 377 | Lilly USA, LLC ($127,634) |
| 2019 | $640,390 | 660 | Amarin Pharma Inc. ($117,265) |
| 2018 | $680,825 | 727 | Amarin Pharma Inc. ($143,444) |
| 2017 | $696,519 | 811 | Amarin Pharma Inc. ($120,579) |
All Payment Transactions
4,245 individual payment records from CMS Open Payments — Page 1 of 170
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,131.00 | General |
| 12/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Obesity | ||||||
| 12/19/2024 | Canon Medical Informatics, Inc. | Vitrea V-Score (Device), Vitrea Advanced Visualization | Honoraria | Cash or cash equivalent | $2,999.00 | General |
| Category: Medical Imaging Software | ||||||
| 12/18/2024 | Corcept Therapeutics | Korlym (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,430.00 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $31.24 | General |
| 12/17/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $250.00 | General |
| Category: Coronary | ||||||
| 12/16/2024 | Cleerly, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 12/16/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $143.48 | General |
| Category: Coronary | ||||||
| 12/16/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Coronary | ||||||
| 12/13/2024 | HEARTFLOW, INC. | FFRct (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,300.00 | General |
| Category: Coronary | ||||||
| 12/13/2024 | HEARTFLOW, INC. | FFRct (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Coronary | ||||||
| 12/12/2024 | Lexicon Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| 12/12/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $268.50 | General |
| Category: Coronary | ||||||
| 12/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $37.50 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | Canon Medical Informatics, Inc. | Vitrea V-Score (Device), Vitrea Advanced Visualization | Honoraria | Cash or cash equivalent | $1.00 | General |
| Category: Medical Imaging Software | ||||||
| 12/11/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $390.81 | General |
| Category: Coronary | ||||||
| 12/11/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $73.51 | General |
| Category: Coronary | ||||||
| 12/11/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $45.00 | General |
| Category: Coronary | ||||||
| 12/11/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $18.27 | General |
| Category: Coronary | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $135.48 | General |
| Category: Coronary | ||||||
| 12/05/2024 | HEARTFLOW, INC. | FFRct (Device) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: Coronary | ||||||
| 12/04/2024 | Novo Nordisk Inc | Ozempic (Drug) | Consulting Fee | Cash or cash equivalent | $3,118.50 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Consulting Fee | Cash or cash equivalent | $3,118.50 | General |
| Category: Diabetes | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Consulting Fee | Cash or cash equivalent | $1,782.00 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EX9924-4473 | Novo Nordisk Inc | $18,182 | 8 |
| CKJX839D12303 | Novartis Pharma AG | $13,800 | 2 |
| ERTUGLIFLOZIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| NN9535-4321 & EX9924-4473 | Novo Nordisk AS | $1,794 | 8 |
| EX9536-4388 | Novo Nordisk AS | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 3,193 | 81,121 | $2.2M | $520,065 |
| 2022 | 22 | 3,003 | 63,553 | $1.8M | $426,242 |
| 2021 | 19 | 2,832 | 64,117 | $1.4M | $331,887 |
| 2020 | 21 | 2,209 | 55,746 | $1.2M | $263,584 |
Total Patients
11,237
Total Services
264,537
Medicare Billing
$1.5M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 1,065 | 1,067 | $1.1M | $275,857 | 25.1% |
| 0501T | Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | Office | 2023 | 142 | 144 | $576,000 | $134,071 | 23.3% |
| 75571 | Ct scan of heart with evaluation of blood vessel calcium | Office | 2023 | 402 | 402 | $148,740 | $37,145 | 25.0% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 59 | 60 | $78,600 | $19,575 | 24.9% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 1,097 | 78,992 | $79,066 | $9,153 | 11.6% |
| 77078 | Ct scan for measuring calcium and other minerals in bone | Office | 2023 | 80 | 80 | $27,495 | $9,147 | 33.3% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 59 | 62 | $33,790 | $7,657 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 54 | $23,220 | $5,648 | 24.3% |
| 70498 | Ct scan of blood vessels of neck with contrast | Office | 2023 | 23 | 23 | $21,390 | $3,898 | 18.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $13,376 | $3,248 | 24.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 14 | 14 | $10,080 | $2,547 | 25.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 49 | 49 | $32,830 | $2,362 | 7.2% |
| 71275 | Ct scan of blood vessels of chest with contrast | Office | 2023 | 12 | 12 | $11,280 | $2,178 | 19.3% |
| 71270 | Ct scan of chest before and after contrast | Office | 2023 | 11 | 11 | $8,910 | $1,882 | 21.1% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 14 | 14 | $9,660 | $1,830 | 18.9% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 49 | 49 | $7,105 | $1,704 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 16 | $4,880 | $1,216 | 24.9% |
| 70460 | Ct scan head or brain with contrast | Office | 2023 | 11 | 11 | $6,160 | $921.50 | 15.0% |
| J3490 | Unclassified drugs | Office | 2023 | 29 | 36 | $3,115 | $26.57 | 0.9% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2022 | 820 | 824 | $848,720 | $212,746 | 25.1% |
| 0501T | Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | Office | 2022 | 62 | 63 | $252,000 | $58,733 | 23.3% |
| 75571 | Ct scan of heart with evaluation of blood vessel calcium | Office | 2022 | 548 | 550 | $203,500 | $49,271 | 24.2% |
| 0503T | Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, analysis of fluid dynamics | Office | 2022 | 19 | 19 | $76,000 | $17,422 | 22.9% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2022 | 44 | 44 | $57,640 | $14,868 | 25.8% |
| 77078 | Ct scan for measuring calcium and other minerals in bone | Office | 2022 | 126 | 126 | $41,455 | $13,886 | 33.5% |
About Dr. Matthew Budoff, M.D
Dr. Matthew Budoff, M.D is a Cardiovascular Disease healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811967433.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Budoff, M.D has received a total of $5.0M in payments from pharmaceutical and medical device companies, with $1.0M received in 2024. These payments were reported across 4,245 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($3.5M).
As a Medicare-enrolled provider, Budoff has provided services to 11,237 Medicare beneficiaries, totaling 264,537 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Torrance, CA
- Active Since 01/25/2006
- Last Updated 02/24/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1811967433
Products in Payments
- Vascepa (Drug) $471,566
- JARDIANCE (Drug) $463,144
- Repatha (Biological) $340,036
- NEXLIZET (Drug) $301,982
- ELIQUIS (Drug) $277,342
- VERQUVO (Drug) $248,931
- PRALUENT (Drug) $247,465
- FARXIGA (Drug) $239,248
- INVOKANA (Drug) $216,931
- Ozempic (Drug) $182,053
- XARELTO (Drug) $167,636
- PRALUENT ALIROCUMAB INJECTION (Biological) $157,910
- BRILINTA (Drug) $147,705
- TRULICITY (Drug) $141,738
- EVKEEZA (Biological) $101,986
- FFRct (Device) $55,263
- LEQVIO (Drug) $44,776
- RYBELSUS (Drug) $42,155
- ZEPBOUND (Drug) $37,021
- Victoza (Drug) $29,916
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Torrance
Ronald Oudiz, M.d, M.D
Cardiovascular Disease — Payments: $836,408
Cardiovascular Disease $836,408
Dr. Rishi Kaushal, M.d, M.D
Cardiovascular Disease — Payments: $108,970
Cardiovascular Disease $108,970
Dr. Matthew Ostrom, M.d, M.D
Cardiovascular Disease — Payments: $57,874
Cardiovascular Disease $57,874
Joseph Thomas, Md, MD
Cardiovascular Disease — Payments: $52,485
Cardiovascular Disease $52,485
Dr. Leonard Scuderi, M.d, M.D
Cardiovascular Disease — Payments: $42,878
Cardiovascular Disease $42,878
Dr. Jashdeep Dhoot, M.d, M.D
Cardiovascular Disease — Payments: $21,247
Cardiovascular Disease $21,247